TransMedics Group, Inc. (NASDAQ:TMDX) is set to announce third quarter earning results on Wednesday 4th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, TMDX to report 3Q20 loss of $ 0.32 per share.
For the full year, analysts anticipate top line of $ 24.77 million, while looking forward to loss of $ 1.42 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 40.00 million ~ $ 43.00 million
Click Here For More Historical Outlooks Of TransMedics Group, Inc.
Previous Quarter Performance
TransMedics Group, Inc. announced loss for the second quarter of $ 0.36 per share, from the revenue of $ 3.39 million. Street analysts expected TransMedics Group, Inc. to report loss of $ 0.43 per share on revenue of $ 2.75 million for the second quarter. The bottom line results beat street analysts by $ 0.07 or 16.28 percent, at the same time, top line results outshined analysts by $ 0.64 million or 23.27 percent.
Stock Performance
Shares of TransMedics Group, Inc. traded up $ 0.68 or 5.71 percent on Tuesday, reaching $ 12.59 with volume of 93.20 thousand shares. TransMedics Group, Inc. has traded high as $ 12.77 and has cracked $ 11.81 on the downward trend
According to the previous trading day, closing price of $ 12.59, representing a 17.92 % increase from the 52 week low of $ 10.10 and a 43.26 % decrease over the 52 week high of $ 20.99.
The company has a market capital of $ 341.88 million and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 8th October 2020, downgraded by JPMorgan Chase & Co. to Neutral from Overweight rating.
Conference Call
TransMedics Group, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.transmedics.com
Transmedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers.
